



**NEWBORN SCREENING PANEL**

**Cumulative Prevalence from 1996 to December 2021\***

Disorders	Screened	Confirmed	Prevalence
<b>Endocrine Disorders</b>			
Congenital Hypothyroidism (CH)	16,368,347	6,179	1:2,649
Congenital Adrenal Hyperplasia (CAH)	16,368,347	795	1:20,589
<b>Amino Acid Disorders</b>			
Phenylketonuria (PKU) (20 Classic, 25 Mild, 11 PTPS Def, 73 Hyperphe)	16,368,347	129	1:126,886
Maple Syrup Urine Disease (MSUD)	12,593,564 <sup>a</sup>	188 <sup>b</sup>	1:66,987
Other Amino Acids (AA) (2 MAT, 10 TYR)	4,408,744 <sup>c</sup>	12	1: 367,395
Fatty Acid Oxidation Disorders (FAOD) (11 CPT1, 7 CUD, 1 GA2, 67 MCAD, 18 VLCAD)	4,408,744 <sup>c</sup>	104	1:42,391
Organic Acid Disorders (OAD) (26 3MCC, 34 GA1, 3 IVA, 5 MMA, 3 PA, 1 MCD)	4,408,744 <sup>c</sup>	72	1:61,232
Urea Cycle Defect (UCD) (5 CIT, 4 ASA)	4,408,744 <sup>c</sup>	9	1: 489,860
Galactosemia (GAL) (33 Classical, 116 Non-Classical)	16,368,347	149	1:109,854
Glucose-6-Phosphates-Dehydrogenase Deficiency (G6PD Def)	16,289,249 <sup>d</sup>	254,883	1:63
Biotinidase Deficiency (BTD)	4,408,744 <sup>c</sup>	1	1:4,408,744
Cystic Fibrosis (CF)	4,408,744 <sup>c</sup>	1	1:4,408,744
<b>Total</b>		<b>262,522</b>	

**Note:**

\*Based on annual submissions of the seven (7) Newborn Screening Centers: 1) NSC- National Institutes of Health [since 1998], 2) NSC- Visayas [since 2006], 3) NSC-Mindanao [since 2009], 4) NSC-Central Luzon [since 2010], 5) NSC-Southern Luzon [since 2013], 6) NSC-Northern Luzon [since 2017], and NSC-Central Visayas [since 2020]

<sup>a</sup> Difference in total screened as MSUD was included in the panel in 2012

<sup>b</sup> Corrections and adjustment made from Prevalence 2020

<sup>c</sup> Difference in total screened as ENBS [other AA, FAOD, OAD, UCD, BTD, CF] were added in 2014

<sup>d</sup> G6PD Def was added in 2000

Prepared by:

**MA ELOUISA REYES**  
 Project Development Officer IV

Certified by:

**MICHELLE E. ABADINGO, MD, FPPS**  
 Director